The value of BioFuture’s drug pipeline, number of drugs currently in development, quality of drugs (likelihood of success), potential revenues and profits
BioFuture’s R&D capabilities (future drug pipeline), scientific talent, intellectual property (for example, patents, proprietary processes or know-how for biologicals research), and buildings, equipment, and other items that allow BioFuture’s R&D to operate.
BioFuture’s marketing or sales capabilities. Especially how promotional messages will be delivered, for example, relationships with key opinion leaders that can promote biologicals; key opinion leaders can come from the academic arena, like prominent medical school professors, or from the public arena, like heads of regulatory bodies or prominent telejournalists.
Acquisition price.

A very good answer might also include multiple additional key factors GlobaPharm should consider:

BioFuture’s existing partnerships or other relationships with pharmacos.
GlobaPharm’s capability gaps in biologicals, R&D, sales and marketing, etc.
GlobaPharm’s alternatives to this acquisition. Alternative companies GlobaPharm could acquire. Other strategies for entering biological segment, for example, entering partnerships rather than acquiring, and pursuing other strategies than entering the biological segment

GlobaPharm Question 1 Reveal